Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
Kian Behbakht, Michael W. Sill, Kathleen M. Darcy, Stephen C. Rubin, Robert S. Mannel, Steven Waggoner, Russell J. Schilder, Kathy Q. Cai, Andrew K. Godwin, R. Katherine AlpaughVolume:
123
Année:
2011
Langue:
english
Pages:
8
DOI:
10.1016/j.ygyno.2011.06.022
Fichier:
PDF, 763 KB
english, 2011